Articles tagged with Prostate Cancer
A study of men with a family history of prostate cancer discovered an inherited form of prostate cancer linked to the mutated gene WNT9B. This gene variant increases prostate cancer risk by two- to 12-fold, comparable to breast cancer risk conferred by pathogenic mutations.
A systematic review found that genomic classifier tests can influence risk classifications and treatment decisions for patients with localized prostate cancer, but more research is needed to understand their cost-effectiveness and impact on racial groups. The tests may lead to more conservative management options, such as active survei...
A group of Chinese experts has developed a comprehensive consensus aimed at addressing critical gaps in prostate cancer management. The consensus recommends starting PSA screening at age 50 and endorsing the use of next-generation hormonal agents combined with ADT for high-volume metastatic castration-sensitive prostate cancer patients.
The new NCCN Guidelines for Patients: Genetic Testing for Hereditary Breast, Ovarian, Pancreatic, and Prostate Cancer provide evidence-based recommendations for assessing and testing for inherited genetic mutations. The resource aims to inform individuals about their cancer risks based on personal or family history.
Researchers developed a novel approach using lipid nanoparticles to deliver mRNA and siRNA, restoring tumor suppressors and inhibiting tumor drivers in prostate cancer cells. This technique holds promise for treating various types of cancer by targeting specific pathways related to tumor growth and suppression.
Researchers are investigating a water vapor system that uses small, targeted amounts of steam to kill cancer cells in patients with intermediate-risk prostate cancer. The trial aims to explore the safety and effectiveness of this treatment as an alternative to traditional therapies, which can cause life-altering side effects.
A new study found that nearly half of high-risk prostate cancer patients have metastatic disease when evaluated with advanced PSMA-PET imaging, suggesting traditional imaging may underestimate cancer spread. This challenge the interpretation of previous studies like EMBARK trial, and support the inclusion of PSMA-PET for patient select...
Most study participants struggled to understand standard prostate cancer pathology reports, but found patient-centered reports easier to comprehend. PCPRs reduced perceived worry in low-risk conditions compared to traditional reports, suggesting their inclusion could enhance patient care.
A study by Charité – Universitätsmedizin Berlin found that an MRI-first approach to detecting prostate cancer is safe and reliable, with normal MRI findings indicating a low risk of aggressive cancer. The strategy involves regular urological checks instead of biopsies for patients without suspicious findings.
Researchers discovered a novel vulnerability in prostate cancer cells that starves them of critical nutrients called amino acids. By inhibiting two proteins, GCN2 and p53, the team found a way to effectively destroy prostate tumors.
Researchers discovered a novel platinum complex that targets androgen receptor signaling, inhibiting cell growth and survival in prostate cancer cells. The complex, 5-H-Y, showed stronger cytotoxic effects than cisplatin with minimal toxicity, offering a promising approach to treating advanced prostate cancer.
A new study found that a low omega-6, high omega-3 diet with fish oil supplements significantly reduced prostate cancer cell proliferation in men. The findings suggest that dietary changes could potentially delay or prevent the need for more aggressive treatments.
Researchers at MSU are developing a novel approach to combat prostate cancer using promethium-149, a radioactive isotope that can deliver high doses of radiation directly to cancer cells. The team plans to test the effectiveness of 149Pm against industry-standard 177Lu and explore its potential for treating other types of cancers.
A new DNA sequencing test called AR-ctDETECT has been found to distinguish between patients with poor and favorable prognoses in advanced prostate cancer. The test identified circulating tumor DNA in 59% of patients and showed that detectable ctDNA was associated with worse overall survival.
The study estimated that prevention, screening, and treatment efforts in the US led to an average of 8 out of 10 cancer deaths being avoided for breast, cervical, colorectal, lung, and prostate cancers combined. The total number of averted cancer deaths was approximately 5.94 million between 1975 and 2020.
Researchers activate glycoprotein 130 and its associated signaling pathway to slow down tumor growth in prostate cancer, stimulating immune system to fight tumour cells. Studies of tissue samples from prostate cancer patients show positive correlation with better survival rates.
Researchers have identified UBA1 enzyme as key mediator for immune response to tumors, inhibiting its activity increases T-cell recruitment and lowers tumor resistance. Pairing UBA1 inhibitors with immune checkpoint blockade therapies may make immunotherapy more effective for patients with 'cold' tumors.
Researchers found that immunosuppression in prostate cancer is associated with a specialised epithelial subtype. This interaction between the immune system and club-like epithelial cells can lead to treatment resistance in patients with advanced, treatment-resistant prostate cancer.
Between 2010 and 2020, there was a significant rise in the use of active surveillance and watchful waiting for patients with intermediate-risk prostate cancer. This trend corresponds to better long-term results and advancements in imaging and risk stratification.
A new study by Weill Cornell Medicine scientists reveals that the enzyme EZH2 drives aggressive tumor growth in treatment-resistant prostate cancers. The absence of protein PKCλ/ι enables EZH2's alternative function, promoting cancer progression despite androgen receptor inhibitors.
A new mathematical model of prostate cancer has been developed, revealing key findings on genetic changes and tumour growth. The study shows that strong genetic changes are necessary for aggressive tumours to develop early in the course of tumour development.
Patients receiving MRI-guided SBRT experienced significantly fewer urinary and bowel side effects compared to CT-guided treatment. MRI guidance also correlated with improved scores on specific quality-of-life measures, including bowel function and sexual health.
A Chinese Medical Journal study reveals that patients with prostate cancer can undergo surgical removal without a pre-operative biopsy, using a combination of mpMRI and PSMA PET/CT imaging. This approach reduces costs and complications associated with traditional biopsy methods.
Researchers have discovered a new strategy to overcome docetaxel resistance in advanced prostate cancer patients, which may improve the efficacy of chemotherapy and prolong overall survival. The approach involves inhibiting cholesterol and lipid biosynthesis, reinducing sensitivity to the drug docetaxel.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with advanced small cell bladder cancer and small cell/neuroendocrine prostate cancer. The study found that the combination treatment resul...
A recent study has uncovered a genetic variant in the PSA gene that is associated with aggressive prostate cancer. This finding could lead to the development of a novel point-of-care device that can identify high-risk patients with low blood PSA levels, enabling early detection and treatment.
A new study by Cedars-Sinai reveals that significant percentages of older men with intermediate- and high-risk prostate cancers are being subjected to aggressive treatments that may not extend their lives, highlighting the need for a more personalized approach to cancer treatment. The study suggests that better estimation, communicatio...
A new strategy for treating prostate cancer has been developed by blocking the GP130 signalling pathway, contrary to current medical understanding. The study found that activating GP130 in prostate cells reduces tumour growth and stimulates the immune system to fight cancer cells.
A comprehensive analysis of 52,000 men with prostate cancer treatment found substantial long-term risks of urinary and sexual complications. Men treated with radiotherapy faced a threefold risk of bladder cancer diagnosis, while those who underwent prostatectomy had a sixfold increased risk of complications.
Researchers have identified 22 pesticides consistently linked to prostate cancer incidence across US counties, including 2,4-D. Four pesticides are also associated with increased prostate cancer mortality rates.
Researchers developed an AI model that can identify and measure aggressive prostate cancer lesions with high accuracy. The model's estimates of tumor size were associated with the likelihood of cancer recurrence or metastasis.
A new discovery by Cold Spring Harbor Laboratory's Lloyd Trotman suggests that menadione, a precursor to vitamin K, can slow prostate cancer progression in mice. The supplement depletes a lipid called PI(3)P, killing cancer cells and slowing disease progression significantly.
UTEP researchers developed a portable device that can detect colorectal and prostate cancer quickly and accurately, reducing the need for costly instruments. The device is low-cost, sensitive, and analyzes samples in just an hour.
A new study from the University of Texas at Arlington suggests that analyzing RNA in urine can show changes in cell types, revealing early signs of cancer and other diseases. This method could help clinicians detect problems earlier when they are more easily treated without invasive procedures.
The UCLA Urology department has been awarded $6 million to continue the IMPACT program, providing comprehensive prostate cancer treatment for underinsured and uninsured Californians. The program has helped over 2,300 men receive treatment services since its inception.
A new study suggests that a healthy diet may help keep low-grade prostate cancer from progressing to more aggressive states in men undergoing active surveillance. The research team led by Johns Hopkins Medicine found that a reduced risk of prostate cancer progression is associated with a healthy diet.
Researchers at Duke University Medical Center found that Black men with metastatic prostate cancer have the greatest survival benefit from sipuleucel-T immunotherapy, possibly due to a genetic variant that encourages an inflammatory response. The study could lead to targeted treatment for patients who will benefit most
A groundbreaking study has demonstrated the clinical success of a new nanoparticle-based, laser-guided therapy for prostate cancer treatment. The therapy successfully eliminated cancerous cells in 73% of patients after 12 months while preserving key functions and side effects.
Researchers found that fermented black garlic extract reduced tumor aggressiveness parameters, including cell proliferation, without affecting normal prostate cells. The extract altered key signaling pathways related to inflammation, suggesting its potential as a dietary supplement to prevent or slow down prostate cancer progression.
Researchers identified three genetic regions strongly associated with increased prostate incidence in a diverse group of African men. The study, the largest of its kind in Africa, may lead to new treatment possibilities and refined screening methods.
Researchers analyzed changes in 72 pairs of microRNAs in patients' blood extracellular vesicles before and after radical prostatectomy, identifying significant changes in 11 miRNA ratios. The study suggests a potential new biomarker for monitoring treatment efficacy and predicting cancer relapse.
Recent clinical trials of neoadjuvant therapy before radical prostatectomy, such as the ACDC-RP trial, have struggled to show significant survival benefits. Researchers recommend maximal androgen blockade with an androgen receptor pathway inhibitor as the 'backbone' of neoadjuvant therapy trials.
A recent study published in The Prostate used genetically modified mice to investigate the relationship between gut dysbiosis and prostate cancer. The researchers found that both humans and mice exhibited marked differences in their gut microbiome composition, with certain bacteria positively associated with prostate cancer. Additional...
A non-invasive blood test measuring circulating tumor cells can predict treatment response, disease progression, and overall survival in men with metastatic prostate cancer. Patients with more CTCs had shorter median survival lengths and a greater risk of death.
Researchers at Michigan Medicine have discovered a new subtype of aggressive prostate cancer and identified a potential degrader to target it. The study found that a genetic alteration in the CDK12 gene drives cancer development, and a degrader targeting this gene shows promise in destroying cancer cells.
Researchers propose reevaluating nomenclature for low-grade prostate cancer, a condition that rarely metastasizes or causes symptoms. This shift aims to balance detection with treatment to reduce harms of overdiagnosis and overtreatment.
A multi-center phase III trial found photon- and proton-based radiation therapies to be similarly safe and effective in treating low- and intermediate-risk prostate cancer. Patients treated with either IMRT or proton therapy reported no significant differences in quality of life, tumor control, or progression-free survival.
UCLA investigators presented data on chemoradiotherapy in rectal cancer, MRI-guided radiotherapy for prostate cancer, and symptom self-reporting during treatment. Researchers developed a predictive model to identify patients most likely to respond to chemoradiotherapy in rectal cancer.
A new study has found that baseline testosterone, age, and duration of ADT are key predictors of testosterone recovery. The researchers developed a nomogram to estimate recovery times based on patient-specific characteristics, providing valuable insights for improving patient outcomes.
Researchers at Cold Spring Harbor Laboratory create a roadmap of how prostate cancer spreads throughout the body, showing that aggressive cells seed cancer's rare migrations to bones, liver, lungs, and lymph nodes. The new technology offers a clearer picture of cancer spread and could lead to more targeted therapeutics.
A new study by the University of Eastern Finland found that pro-inflammatory macrophages can transform prostate cancer cells into stem-like cells, making them resistant to treatment. The study reveals that these immune cells secrete factors that increase the expression of stem cell markers in prostate cancer cells.
A study published in Nature Communications found that the MYC gene is a common culprit driving prostate cancer progression. The research reveals how MYC activation attracts immune cells to the tumor but later helps hide it from immune detection, making it undetectable.
A new prostate biopsy technique, transperineal biopsy, has been shown to lower the risk of infection compared to traditional biopsies. The PREVENT trial found no infections among men who underwent the transperineal procedure, while those with traditional transrectal biopsies had a 1.6% infection rate despite receiving antibiotics.
A new study found that immunotherapy can effectively treat prostate cancer in men with a specific genetic type, slowing disease progression by four to 33 months. This treatment approach may be beneficial for approximately 4-5% of patients, who experience significant cancer control.
A new study by Michigan Medicine found that the Inflation Reduction Act's limit on Medicare Part D spending leads to significant savings for cancer patients prescribed oral chemotherapy. The average annual cost for these medications decreased from $11,284 in 2023 to $3,927 in 2024, resulting in median cost savings of $7,260.
A new study has identified NSD2 as a fundamental factor in early stages of prostate cancer development, found to alter androgen receptor function leading to rapid cell division and growth. The study may suggest a new way to therapeutically target prostate cancer by targeting the epigenetic component NSD2.
A new AI model generates detailed images of cancer tissue that imitate what its staining would look like, reducing the need for resource-intensive lab analyses. The VirtualMultiplexer uses contrastive unpaired translation to create accurate virtual pictures of diagnostic tissue colorations.
Researchers discovered that low testosterone levels stimulate cancer cell proliferation, while high doses cause differentiation and suppress growth. This finding could help physicians select patients for bi-polar androgen therapy, a technique using monthly high-dose testosterone injections.
Rates of prostate cancer across Europe more than doubled from 1990 to 2017, with highest increases in northern Europe, France, and the Baltic countries. Death rates were lower, sparking concerns about overdiagnosis and unnecessary treatment, emphasizing the need for carefully planned screening programs.
Researchers developed a novel compound to target prostate cancer using radioactive atom astatine-211, potentially overcoming issues with previous compounds like deastatination. The study found high accumulation in tumors and low accumulation in vital organs, highlighting the potential of this new compound for targeted alpha therapy.